Author(s):
Ram D. Bawankar, Prasad P. Jumade
Email(s):
rambawankar2008@rediffmail.com
DOI:
10.52711/0974-360X.2026.00341 
Address:
Ram D. Bawankar1*, Prasad P. Jumade1
1,2Agnihotri College of Pharmacy, Bapuji Wadi, Ramnagar, Wardha – 442001, affiliated to Rashtrasant Tukdoji Maharaj Nagpur University, Nagpur, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
Recent studies and new discoveries on hydrocolloid based Orodispersible strips (ODSs) are consolidated in the present review. produced through 3D printing, and particular focus on the formulation strategies of BCS IIdrugs was put. The 3D (3 dimensional) printing technologies, characterization, and the projections in the future. ODS have emerged as a patient-centric dosage form, particularly suited for paediatric, geriatric, and dysphagic populations. Hydrocolloids, owing to their excellent film-forming, fast disintegration, and biocompatibility properties, widely used as polymeric bases for ODS. As 3D printing has gained attention as an advanced manufacturing method and emerged as a flexible platform for manufacturing orodispersible strips (ODSs) which enables precise dose personalization, innovative multilayer structures, and novel release profiles. The integration of hydrocolloids polymers (natural and semi-synthetic) based ODs formulations marks a significant breakthrough due to its hydrophilicity, biocompatibility and rapid disintegration, thus enhancing the efficiency of BCS IIdrugs delivery and broadening the scope for such drugs biddable to this route.
Cite this article:
Ram D. Bawankar, Prasad P. Jumade. Hydrocolloid Based Orodispersible Strip of BCS II Drug via 3D Printing – An Outline. Research Journal Pharmacy and Technology. 2026;19(5):2381-9. doi: 10.52711/0974-360X.2026.00341
Cite(Electronic):
Ram D. Bawankar, Prasad P. Jumade. Hydrocolloid Based Orodispersible Strip of BCS II Drug via 3D Printing – An Outline. Research Journal Pharmacy and Technology. 2026;19(5):2381-9. doi: 10.52711/0974-360X.2026.00341 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-5-62
8. REFERENCES:
1. Steele CM, et al. The prevalence of dysphagia. Dysphagia. 2015; 30(2): 275–81.
2. European Pharmacopoeia. Orodispersible Films. 10th ed. EDQM; 2020.
3. Hemant A. Deokule, Smita S. Pimple, Praveen D. Chaudhari, Ajit S. Kulkarni. Fabrication and Evaluation of Mouth Dissolving Strips of Metoclopramide Hydrochloride by Using Novel Film Former. Research Journal of Pharmacy and Technology. 2021; 14(10): 5515-0.
4. ISO/ASTM 52900:2015. Additive manufacturing - General principles - Terminology.
5. Trenfield SJ, Awad A, Goyanes A, Gaisford S, Basit AW. 3D printing pharmaceuticals: drug development to frontline care. Trends Pharmacol Sci. 2018; 39(5): 440–51.
6. Dickinson E. Hydrocolloids as emulsifiers and emulsion stabilizers. Food Hydrocoll. 2009; 23(6): 1473–82.
7. Mariod AA, Fadul H. Gelatin, source, extraction and industrial applications. Acta Sci Pol Technol Aliment. 2013; 12(2): 135–47.
8. Preis M, Woertz C, Kleinebudde P. Film-based dosage forms for oral administration. Drug Discov Today. 2014; 19(1): 107–13.
9. Kukec S, Planinšek O, Srčič S, Gašperlin M. Fast dissolving pullulan films loaded with nanoparticles for enhanced dissolution of poorly water-soluble drugs. Drug Dev Ind Pharm. 2019; 45(9): 1500–8.
10. Irfan M, Rabel S, Bukhtar Q, Qadir MI, Jabeen F, Khan A. Orally disintegrating films: a modern expansion in druamidong delivery system. Saudi Pharm J. 2015; 24(5): 537–46.
11. Raghavendra Rao NG, Kulkarni U, Patel B, Dave BS. Formulation and in vitro evaluation of sodium alginate based oral films of ondansetron hydrochloride. Indian J Pharm Educ Res. 2014; 48(S2): 27–33.
12. Cilurzo F, Cupone IE, Minghetti P, Selmin F, Gennari CG, Montanari L. Fast dissolving films made of maltodextrins. Eur J Pharm Biopharm. 2010; 70(3): 895–900.
13. Perumal VA, Lutchman D, Mackraj I, Govender T. Formulation of monolayered films with drug and polymers of opposing solubilities. Int J Pharm. 2008; 358(1–2):184–91.
14. Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv. 2011; 8(3): 299–316.
15. Visser JC, et al. Orodispersible films in pharma. J Control Release. 2015; 205: 1–9.
16. Cilurzo F, et al. Film-forming polymers in oral films. AAPS PharmSciTech. 2011; 12(4): 1101–8.
17. Cilurzo F, Selmin F, Aluigi A, Minghetti P. Maltodextrin and CMC oral films. J Pharm Sci. 2012; 101(11): 4128–34.
18. Musazzi UM, et al. Influence of HPMC/HPC blends on film solubility and drug dispersion. Int J Pharm. 2018; 535(1–2):250–8.
19. Borges AF, Silva C, Coelho JF, Simões S. Oral films: current status and future perspectives. J Control Release. 2015; 206: 1–19.
20. Preis M, Knop K, Breitkreutz J. Manufacturing of orodispersible films using PVA. Drug Dev Ind Pharm. 2014; 40(2): 270–9.
21. Dixit RP, Puthli SP. PVA-based and pullulan-based films in ODS. J Control Release. 2009; 139(2): 94–107.
22. Zhang H, Shen Z. PVP-based film systems for poorly soluble drugs. Int J Pharm. 2015; 490(1–2): 1–10.
23. Camlesh R. Sunitha, S. Madhavi Latha, M. Pavani, K. Anjali, D. Durga Siva Prasad, M. Lakshmi Mounika, Hanumayamma, Ch. Kalavathi, Gurappa, SK. Inthiyaz. Design and Optimization of Hydrodynamically Balanced Regioselective Controlled Release Drug Delivery of BCS Class II Drug by using Natural and Synthetic Polymers. Asian Journal of Pharmacy and Technology. 2025; 15(2): 107-5.
24. Hemanth KG, Hemamanjushree S, Abhinaya N, Raveendra Pai, Girish Pai K. 3D Printing: A Review on Technology, Role in Novel Dosage Forms and Regulatory Perspective. Research J. Pharm. and Tech. 2021; 14(1): 562-572.
25. Mishra R, Amin A. Formulation and characterization of rapidly dissolving films of cetirizine hydrochloride using pullulan as a film-forming agent. J Pharm Res. 2011; 4(6): 2119–23.
26. Imeson A. Food Stabilisers, Thickeners and Gelling Agents. Wiley-Blackwell; 2011.
27. Thakur N, Bansal M, Sharma N. Development of HPMC-based fast dissolving oral films. J Drug Deliv Sci Technol. 2019; 52: 110–9.
28. Preis M, et al. Rolling method for oral films. Drug Dev Ind Pharm. 2014; 40(2): 270–9.
29. Cilurzo F, et al. Maltodextrin-based films: properties and applications. Eur J Pharm Biopharm. 2011; 78(2):193–8.
30. Tiryaki O, et al. Pre-gelatinized starch–HPMC films for desloratadine. J Drug Deliv Sci Technol. 2020; 55:101475.
31. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification. Pharm Res. 1995; 12(3): 413–20.
32. Mukund Tawar, Kiran Raut, Reshma Chaudhari, Nikita Jain. Novel Methods to Enhance Solubility of Water Insoluble Drugs. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(2): 151-6.
33. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. J Pharm Pharmacol. 2010; 62(4): 361–70.
34. Hoffmann EM, et al. Solvent casting method for ODFs. Eur J Pharm Biopharm. 2011; 78(1): 56–62.
35. Preis M, et al. Rolling method for oral films. Drug Dev Ind Pharm. 2014; 40(2): 270–9.
36. Fule R, Amin P. Hot melt extrusion for film formulations. Int J Pharm. 2014; 461(1–2): 167–74.
37. Senta-Loys Z, Bourret E, Arnaud P, Sergent M. Orodispersible films: a modern way to oral drug delivery. Eur J Pharm Biopharm. 2017; 119: 150–66.
38. Preis M. Orally disintegrating films and mini-tablets—innovative dosage forms for pediatric use. AAPS PharmSciTech. 2015; 16(2): 234–41.
39. Nuha Mohammed Abdulkhaleq, Mowafaq M. Ghareeb. 3D Printing of Baclofen Gastro-Floating Drug Delivery Systems: A Comparison Study with In vitro and In vivo Evaluation. Research Journal of Pharmacy and Technology 2023; 16(1): 363-2.
40. Goyanes A, et al. 3D printing of medicines: Personalized dosage forms. Int J Pharm. 2016; 499(1–2):376–94.
41. Seoane-Viano I, et al. Semi-solid extrusion 3D printing in drug development. Pharmaceutics. 2021; 13(6): 890.
42. Alhnan MA, et al. Emergence of 3D printed dosage forms. Pharm Res. 2016; 33(8):1817–33.
43. Akiladevi D, Raman Suresh Kumar, Arunkumar N. A Review on 3D printing Pharmaceutical Manufacturing and applications on Drug Delivery System. Research J. Pharm. and Tech. 2019; 12(2): 873-875.
44. Kassem MA, ElMeshad AN, Fares AR. Nanomicelle formulation of Ibuprofen for enhanced solubility and dissolution. Int J Pharm. 2020; 588:119729.
45. Jain A, et al. Ketoprofen-loaded PLGA nanoparticles. Drug Dev Ind Pharm. 2015; 41(8): 1345–53.
46. Sharma P, et al. Telmisartan ODF formulations using Gelucire and HPMC. J Drug Deliv Sci Technol. 2021; 63: 102435.
47. FDA. Adalat® (nifedipine) label information. U.S. Food and Drug Administration; 2020.
48. Foster A, et al. Enzalutamide lipid-based formulations. Sci Rep. 2020; 10:874.
49. Giri TK, et al. Formulation of olmesartan ODF using HPMC/PVA. Res J Pharm Tech. 2019; 12(11): 5435–40.
50. Lam JK, et al. Irbesartan ODF development. Int J Pharm. 2014; 477(1–2): 201–8.
51. ElMeshad AN, Ghorab MK. Valsartan ODF formulation study. Saudi Pharm J. 2019; 27(4):531–43.
52. Doan TV, et al. Candesartan cilexetil ODFs prepared using polymer blends. J Drug Deliv Sci Technol. 2022; 67: 102967.
53. Hemant A. Sawarkar, Sachin C. Kale, Ram D. Bawankar, Kailas R. Biyani. Exploring the Biofilm Inhibiting potential of Bunium persicum Essential Oil: A Promising Strategy for Combating Microbial Biofilm. Research Journal of Pharmacy and Technology. 2024; 17(6): 2592-6.
54. Alipour M, et al. Ketorolac-loaded PLGA nanoparticles. Pharmaceutics. 2020; 12(10):955.
55. Singh A, et al. Soluplus-based ibuprofen micelles for enhanced delivery. Int J Pharm Sci Res. 2017; 8(3): 1200–8.
56. Ozyazici M, et al. PLGA microspheres of Ketoprofen. Drug Dev Res. 2013; 74(2):85–94.
57. Passerini N, Albertini B. Modified starches in ODF formulation. Carbohydr Polym. 2019; 222:115–36.
58. ASTM International. Standard terminology for additive manufacturing technologies. ASTM F2792-12a. West Conshohocken (PA): ASTM Int; 2012.
59. Awad A, et al. 3D printing in pharmaceutical dosage forms. J Control Release. 2018; 285: 168–86.
60. Saumya S, Agila Anbuselvan, Poorva S, G. Priya. A Review on 3D Printing Techniques and Scaffolds for Auricular Cartilage Reconstruction. Research J. Pharm. and Tech. 2018; 11(9): 4179-4186.
61. Jamróz W, Kurek M, Jachowicz R. 3D printing for BCS II drugs. Pharmaceutics. 2018; 10(4):204.
62. Nisha C Fernandes, Swati C Jagdale, Anuruddha R Chabukswar, Bhanudas S Kuchekar. Superdisintegrants Effect on Three Model Drugs from Different BCS Classes. Research J. Pharm. and Tech. 2009; 2 (2): 335-337.
63. Khaled SA, et al. Binder jetting in pharma. Int J Pharm. 2015; 494(2): 578–87.
64. Aprecia Pharmaceuticals. Spritam® (levetiracetam) - FDA approval. 2015. (Company/Regulatory announcement).
65. Goyanes A, et al. Challenges in binder jetting of drugs. Int J Pharm. 2015; 487(1–2): 144–50.
66. Frazier WE. Metal additive manufacturing overview. JOM. 2014; 66(10):281–6.
67. Balla VK, et al. Directed energy deposition applications. Mater Sci Eng A. 2010; 527(26): 7305–10.
68. Trenfield SJ, et al. Thermal limitations in AM for drug delivery. Int J Pharm. 2018; 548(1): 586–94.
69. Melocchi A, et al. 3D printing by FDM in pharmaceuticals. Int J Pharm. 2016; 509(1–2): 255–63.
70. Tagami T, et al. Use of PLA and PVA in drug-loaded filaments. Int J Pharm. 2017; 519(1–2): 290–5.
71. Alhijjaj M, Belton P, Qi S. Stability issues in FDM processing. Eur J Pharm Biopharm. 2016; 108:71–9.
72. Goyanes A, et al. SSE 3D printed films. Int J Pharm. 2019; 567: 118481.
73. Tan YJ, et al. Semi-solid extrusion for biopolymers. Sci Rep. 2018; 8: 9139.
74. Trenfield SJ, et al. SSE for personalized medicines. J Control Release. 2019; 304: 39–54.
75. Buanz AB, et al. Inkjet printing pharmaceuticals. Int J Pharm. 2011; 403(1–2):98–102.
76. Maples-Keller JL, et al. TIJ vs PIJ in pharmaceutical printing. Adv Drug Deliv Rev. 2016; 113: 116–34.
77. Kyobula M, et al. Printing APIs onto hydrocolloid films. Int J Pharm. 2017; 524(1–2): 96–104.
78. Scoutaris N, et al. Challenges of nozzle-based printing. J Pharm Sci. 2011; 100(7): 2566–75.
79. Wickström H, et al. Droplet deposition and dose control. Eur J Pharm Sci. 2015; 75: 106–13.
80. Buanz AB, et al. Personalised dosing with inkjet printing. Int J Pharm. 2012; 435(1):1–4.
81. Gibson I, Rosen D, Stucker B. Additive Manufacturing Technologies. 2nd ed. Springer; 2014.
82. Deckard C. Selective Laser Sintering (SLS) patent. US Patent; 1988.
83. Fina F, et al. SLS for pharmaceuticals. Eur J Pharm Biopharm. 2017; 108: 157–66.
84. Davis DA, et al. Limitations of PBF in oral films. Int J Pharm. 2019; 567: 118487.
85. Hafner A, et al. Lamination technologies in pharma. Adv Mater Res. 2019; 114: 267–74.
86. Genina N, Boetker JP, Rantanen J. Laminated multi-layer drug films. Int J Pharm. 2016; 514(1): 256–64.
87. Schuck P, et al. Food and pharmaceutical applications of hydrocolloids. Food Hydrocoll. 2021; 113: 106535.
88. Venkatkrishna J, Preethi Sudheer, Prakruthi MB, Samikcha Rai. An Investigation on Crystal Engineered Rivaroxaban in Developing Orodispersible film. Research Journal Pharmacy and Technology. 2025; 18(12): 5785-2.